JP2022537159A5 - - Google Patents
Info
- Publication number
- JP2022537159A5 JP2022537159A5 JP2021573844A JP2021573844A JP2022537159A5 JP 2022537159 A5 JP2022537159 A5 JP 2022537159A5 JP 2021573844 A JP2021573844 A JP 2021573844A JP 2021573844 A JP2021573844 A JP 2021573844A JP 2022537159 A5 JP2022537159 A5 JP 2022537159A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- seq
- cd79a
- fusion polypeptide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861838P | 2019-06-14 | 2019-06-14 | |
| US62/861,838 | 2019-06-14 | ||
| US202062991314P | 2020-03-18 | 2020-03-18 | |
| US62/991,314 | 2020-03-18 | ||
| PCT/US2020/037145 WO2020252110A1 (en) | 2019-06-14 | 2020-06-11 | Compositions and methods for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537159A JP2022537159A (ja) | 2022-08-24 |
| JP2022537159A5 true JP2022537159A5 (https=) | 2023-06-16 |
| JP7649258B2 JP7649258B2 (ja) | 2025-03-19 |
Family
ID=73780846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573844A Active JP7649258B2 (ja) | 2019-06-14 | 2020-06-11 | 癌を治療するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220280567A1 (https=) |
| EP (1) | EP3983445A4 (https=) |
| JP (1) | JP7649258B2 (https=) |
| KR (1) | KR20220033485A (https=) |
| CN (1) | CN114206936B (https=) |
| AU (1) | AU2020291922A1 (https=) |
| BR (1) | BR112021025259A2 (https=) |
| CA (1) | CA3143248A1 (https=) |
| IL (1) | IL288914A (https=) |
| MA (1) | MA56212A (https=) |
| MX (1) | MX2021015495A (https=) |
| WO (1) | WO2020252110A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3806903T5 (da) * | 2018-06-14 | 2024-08-19 | 2Seventy Bio Inc | Cd79a kimæriske antigenreceptorer |
| AU2021255702A1 (en) * | 2020-04-17 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Modified CCR polypeptides and uses thereof |
| JP2024503249A (ja) * | 2020-12-21 | 2024-01-25 | ２セブンティ バイオ インコーポレイテッド | 部位特異的変異導入のための組成物及び方法 |
| JP2024503508A (ja) | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | 免疫調節性抗体－薬物コンジュゲート |
| BR112023015561A2 (pt) | 2021-02-03 | 2023-11-14 | Univ Minnesota | Compostos imunoestimuiladores e conjugados |
| CA3215830A1 (en) * | 2021-04-19 | 2022-10-27 | Rafael CUBAS | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| IL310550A (en) * | 2021-08-04 | 2024-03-01 | Univ Colorado Regents | LAT-activating chimeric antigen receptor T cells and methods of using them |
| US20230346836A1 (en) * | 2021-12-22 | 2023-11-02 | Crispr Therapeutics Ag | Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof |
| CA3255500A1 (en) | 2022-04-08 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | MULTI-PART RECEIVERS AND SIGNALING COMPLEXES |
| EP4518905A1 (en) | 2022-05-06 | 2025-03-12 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| JP2025520227A (ja) | 2022-05-26 | 2025-07-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レンチウイルスベクターを維持するための組成物及びその使用 |
| JP2025525904A (ja) | 2022-08-03 | 2025-08-07 | シージェン インコーポレイテッド | 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2760891B1 (en) * | 2011-09-26 | 2018-11-07 | JN Biosciences LLC | Hybrid constant regions |
| WO2015121454A1 (en) * | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| WO2015161276A2 (en) * | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
| PL3134432T3 (pl) * | 2014-04-25 | 2020-10-19 | Bluebird Bio, Inc. | Promotor mnd chimeryczne receptory antygenowe |
| TWI632160B (zh) * | 2015-01-16 | 2018-08-11 | 中央研究院 | 具有標的部分及效應部分的分子構建體 |
| JP7065782B2 (ja) * | 2016-03-18 | 2022-05-12 | フレッド ハッチンソン キャンサー リサーチ センター | Ｃｄ２０免疫療法のための組成物および方法 |
| CN105949317B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
| CN109562126A (zh) * | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| ES2981703T3 (es) | 2016-09-02 | 2024-10-10 | Lentigen Tech Inc | Composiciones y métodos para tratar cáncer con DuoCars |
| BR112019006781A2 (pt) * | 2016-10-07 | 2019-07-30 | Novartis Ag | receptores de antígeno quiméricos para o tratamento de câncer |
| EP3336107A1 (en) * | 2016-12-15 | 2018-06-20 | Miltenyi Biotec GmbH | Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor |
| MA48797A (fr) * | 2017-05-25 | 2020-04-08 | Bluebird Bio Inc | Variants de l'endonucléase cblb , compositions et procédés d'utilisation |
| MA51428A (fr) * | 2017-12-22 | 2020-11-04 | Bluebird Bio Inc | Récepteur d'antigène chimérique multivalent |
| DK3806903T5 (da) * | 2018-06-14 | 2024-08-19 | 2Seventy Bio Inc | Cd79a kimæriske antigenreceptorer |
-
2020
- 2020-06-11 WO PCT/US2020/037145 patent/WO2020252110A1/en not_active Ceased
- 2020-06-11 BR BR112021025259A patent/BR112021025259A2/pt unknown
- 2020-06-11 AU AU2020291922A patent/AU2020291922A1/en active Pending
- 2020-06-11 EP EP20821693.7A patent/EP3983445A4/en active Pending
- 2020-06-11 CN CN202080052834.0A patent/CN114206936B/zh active Active
- 2020-06-11 KR KR1020227001320A patent/KR20220033485A/ko not_active Ceased
- 2020-06-11 JP JP2021573844A patent/JP7649258B2/ja active Active
- 2020-06-11 US US17/618,747 patent/US20220280567A1/en active Pending
- 2020-06-11 CA CA3143248A patent/CA3143248A1/en active Pending
- 2020-06-11 MX MX2021015495A patent/MX2021015495A/es unknown
- 2020-06-11 MA MA056212A patent/MA56212A/fr unknown
-
2021
- 2021-12-12 IL IL288914A patent/IL288914A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537159A5 (https=) | ||
| US11932873B2 (en) | Reducing immune tolerance induced by PD-L1 | |
| TWI771677B (zh) | 靶向ｂｃｍａ的工程化免疫細胞及其用途 | |
| US20250296970A1 (en) | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy | |
| TWI771678B (zh) | 靶向ｂｃｍａ的工程化免疫細胞及其用途 | |
| JP7629414B2 (ja) | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ | |
| JP2021527409A5 (https=) | ||
| JP2023522038A5 (https=) | ||
| JP2023539591A5 (https=) | ||
| Pircher et al. | T cell engineering | |
| US20240335538A1 (en) | Novel chimeric antigen receptor and immune cells expressing same | |
| TW202144434A (zh) | 人源化cd19抗體及其應用 | |
| CN110540997A (zh) | 靶向bcma嵌合抗原受体、核酸序列、载体及应用 | |
| WO2024115077A1 (en) | Cd229 and bcma targeting moieties for the treatment of cd229- bcma- positive cancer | |
| LT7127B (lt) | Į bcma nukreipta car-t ląstelių terapija dauginei mielomai gydyti | |
| KR102532260B1 (ko) | 돌연변이 EGFR 및 EphA2를 동시 타겟하는 키메라 항원 수용체 | |
| Burns | The Major Clinical Components of Cancer Immunotherapy (Modulating Cell-Mediated Immune Mechanisms) | |
| Thomas | Updates in Adult Acute Lymphoblastic Leukemia—Current Status of Antigen-targeted Treatments and Immunotherapy | |
| HK40110123A (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| WO2025233431A1 (en) | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof | |
| CN120005830A (zh) | 一种分泌cd47-pd-l1的基因修饰的免疫细胞的制备及应用 | |
| HK40062446B (zh) | 靶向bcma的工程化免疫细胞及其用途 | |
| HK1228783A1 (en) | Reducing immune tolerance induced by pd l1 | |
| HK1228783B (en) | Reducing immune tolerance induced by pd l1 | |
| RU2019113504A (ru) | Химерные антигенные рецепторы для лечения рака |